ADVANCING IMMUNO-ONCOLOGY

About Iovance Biotherapeutics

Iovance Biotherapeutics is a late-stage oncology company with the potential to bring the first novel autologous T cell therapy to the market for solid tumors in patients with significant unmet needs. We are focused on the development, manufacturing and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). TIL therapy is a highly personalized approach in which patients receive a one-time treatment with their own expanded and rejuvenated T-cells to treat cancer.  Also known as adoptive T-cell therapy, TIL therapy was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute. Building from the initial academic process at NCI, our proprietary Iovance TIL technology platform introduces a second-generation process (Gen 2) with manufacturing and logistical efficiencies aimed at further optimizing treatment, decreasing production time and streamlining distribution processes. Through these improvements, more than 400 patients have been treated using the Gen 2 process with a manufacturing success rate above 90%.

Our T cell-based immunotherapy technology platform is potentially applicable to many tumor types and blood cancers. Our lead TIL product candidate lifileucel is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive clinical efficacy following one-time administration for metastatic melanoma and cervical cancer. Lifileucel has the potential to become the first approved cell therapy in solid tumors, and Iovance is actively building a commercial infrastructure and cell therapy manufacturing facility to prepare for launch.

We believe Iovance TIL has the potential to become a mainstay treatment for thousands of people diagnosed with cancer. Additional TIL therapies in the clinic for solid tumors include LN-145 for the treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (HNSCC) and selected TIL (designated LN-145-S1). For blood cancers, we are investigating a peripheral blood lymphocyte (PBL) therapy consisting of a non-genetically modified, polyclonal T cell product that is manufactured from a patient’s blood sample using a nine-day process.

As we continue advancing our technology platform, we aim to establish Iovance as the leader in TIL therapy development, manufacturing and commercialization with the potential to build a broad portfolio of cell therapies for multiple solid tumors and blood cancers.